Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors studied for energy-expenditure, body-weight and liver-fat research.
Survodutide (BI 456906) is a synthetic, lipidated peptide of 29 amino acids based on the glucagon sequence and engineered to activate both the glucagon receptor and the GLP-1 receptor. A C18 fatty-diacid side chain promotes albumin binding and is studied for an extended half-life compared with the native hormones.
Research on survodutide examines how GLP-1 receptor signalling on appetite and glucose handling combines with glucagon-receptor effects on energy expenditure and hepatic lipid metabolism. It is being evaluated in clinical research on obesity and metabolic dysfunction-associated steatohepatitis (MASH) and is a research-only investigational compound.
Studied in metabolic models for combined GLP-1 and glucagon receptor effects on body weight and food intake.
Researched for glucagon-receptor-driven effects on energy expenditure in preclinical models.
Investigated in MASH and liver-fat models for effects on hepatic lipid metabolism and liver fat content.
Examined for GLP-1-receptor-mediated effects on glucose handling and insulin secretion.
Bring the vial (10 mg) and bacteriostatic water to room temperature.
Add bacteriostatic water slowly along the glass wall — the volume you add sets the concentration.
Swirl gently (do not shake) until fully clear, then refrigerate at 2–8 °C.
Studied in research models combining glucagon/GLP-1 dual agonism with amylin-receptor satiety signalling.
Compared in research contrasting dual glucagon/GLP-1 agonism with triple GLP-1/GIP/glucagon agonism.
Links open a PubMed search for the topic. They point to independent literature and are provided for orientation in a research context only.
Survodutide (BI 456906) is an investigational, lipidated glucagon analog that activates both the glucagon receptor and the GLP-1 receptor. It is studied in metabolic and liver-fat research.
Selective GLP-1 receptor agonists act on a single receptor, while survodutide adds glucagon-receptor activity, which research examines for additional effects on energy expenditure and liver fat.
No. Survodutide is an investigational compound that is still being evaluated in clinical studies and has no approved therapeutic use. It is intended for laboratory research only.
You must be at least 21 years old to enter this website.
By clicking "Confirm & Enter", you confirm that you are 21 years of age or older and understand that all products sold on this website are intended for research purposes only.
